Given the important regulatory role of miRNAs in tumor angiogenesis, targeting or delivering miRNAs to tumors holds great promise as a novel therapeutic approach. In this case, it is essential to deliver antagomiRs or miRNA mimics into tumor cells or endothelial cells. As naked miRNAs are hydrophilicity, unable to pass through cell membranes, and could be easily degraded by serum RNase , in vivo application of miRNA requires formulation into delivery systems. Here we summarize some miRNA delivery approaches that have been applied to suppress angiogenesis in vivo (Table 5).Table 5MiRNA-based therapeutics to target tumor angiogenesismiRNAsDelivery systemsCancerTargetsRefmiR-125bPEIlung cancer, colorectal cancerVE-cadherinmiR-192DOPCovarian cancer, renal tumorEGR1, HOXB9miR-200DOPClung cancer, ovarian cancer, renal cancerIL8, CXCL1miR-520dDOPCovarian cancerEphA2miR-132cRGDbreast cancerp120RasGAPmiR-499APRPG-PEGcolorectal cancerVEGFmiR-29a/cCMVsgastric cancerVEGFmiR-150CMVssarcomaVEGFPEI polymer polyethylenimine, DOPC 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine, cRGD cyclicArginine-Glycine-Aspartic acid, APRPG-PEG Ala-Pro-Arg-Pro-Glypeptide-conjugated polyethyleneglycol, CMVs Cell-derived membrane vesicles